XellSmart gains FDA clearance for three iPSC cell therapies
June 03, 2025 | 15:00
New hope emerges for Parkinson’s, spinal injury, and ALS with cutting-edge tech.
XellSmart’s iPSC Therapy for Spinal Injury Approved for Phase I Trial by U.S. FDA
May 26, 2025 | 16:29
In a global first, the allogeneic regenerative treatment marks a breakthrough in spinal cord repair.
I Peace announces new iPSC lines to reduce immune rejection risk for U.S. population
October 30, 2024 | 01:55
Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells and iPSC-derived cell therapies, announced that the company has successfully generated iPS cell lines that are homozygous for HLA A, C, and DPA1.
Mobile Version